Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Director Clay B. Siegall sold 11,346 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $85.01, for a total value of $964,523.46. Following the completion of the sale, the director now directly owns 18,204 shares of the company’s stock, valued at $1,547,522.04. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

RARE opened at $83.81 on Friday. The stock’s fifty day moving average is $82.29 and its two-hundred day moving average is $65.00. The company has a market capitalization of $5.11 billion, a P/E ratio of -16.06 and a beta of 2.22. Ultragenyx Pharmaceutical Inc has a 52 week low of $31.99 and a 52 week high of $91.77. The company has a quick ratio of 4.07, a current ratio of 4.12 and a debt-to-equity ratio of 0.05.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Parametric Portfolio Associates LLC boosted its position in shares of Ultragenyx Pharmaceutical by 17.0% in the 1st quarter. Parametric Portfolio Associates LLC now owns 33,151 shares of the biopharmaceutical company’s stock worth $1,473,000 after purchasing an additional 4,818 shares in the last quarter. State Street Corp raised its stake in shares of Ultragenyx Pharmaceutical by 1.4% during the 1st quarter. State Street Corp now owns 2,229,351 shares of the biopharmaceutical company’s stock valued at $99,050,000 after buying an additional 30,604 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 3.2% during the 1st quarter. Franklin Resources Inc. now owns 382,473 shares of the biopharmaceutical company’s stock valued at $16,993,000 after buying an additional 11,823 shares during the last quarter. Nuveen Asset Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 9.4% during the 1st quarter. Nuveen Asset Management LLC now owns 331,091 shares of the biopharmaceutical company’s stock valued at $14,710,000 after buying an additional 28,322 shares during the last quarter. Finally, BNP Paribas Arbitrage SA increased its stake in shares of Ultragenyx Pharmaceutical by 84.9% in the 1st quarter. BNP Paribas Arbitrage SA now owns 39,832 shares of the biopharmaceutical company’s stock valued at $1,770,000 after purchasing an additional 18,286 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have recently weighed in on RARE shares. Canaccord Genuity increased their price target on Ultragenyx Pharmaceutical from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. Stifel Nicolaus increased their price target on Ultragenyx Pharmaceutical from $70.00 to $82.00 and gave the stock a “buy” rating in a report on Monday, May 18th. Piper Sandler increased their price target on Ultragenyx Pharmaceutical from $70.00 to $83.00 and gave the stock an “overweight” rating in a report on Tuesday, June 30th. Citigroup increased their price target on Ultragenyx Pharmaceutical from $53.00 to $66.00 and gave the stock a “neutral” rating in a report on Friday, May 8th. Finally, Robert W. Baird increased their price target on Ultragenyx Pharmaceutical from $75.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, July 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $81.07.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Featured Story: The risks of owning bonds

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.